癌胚抗原市場規模、佔有率及成長分析（按類型、性別、產品、檢測、最終用戶和地區）－2025-2032 年產業預測

2023 年癌胚抗原市場規模價值 26 億美元，預計將從 2024 年的 27.2 億美元成長到 2032 年的 39.6 億美元，預測期間（2025-2032 年）的複合年成長率為 4.8%。

全球癌胚抗原 (CEA) 市場正在經歷強勁成長，主要原因是癌症發生率上升，尤其是結直腸癌，這是 CEA 檢測的主要應用。人們對癌症早期檢測和監測的日益關注導致對 CEA 等腫瘤標記的需求增加。全球癌症發生率，尤其是大腸直腸癌的快速成長，增加了對高效診斷解決方案的需求，而CEA是常規癌症篩檢的可靠腫瘤標記。免疫測量和生物標記發現等診斷技術的進步正在提高 CEA 檢測的準確性和效率。然而，成本限制仍然是市場擴張的主要障礙，尤其是在新興國家，尤其是醫療保健預算有限的地區。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

癌胚抗原市場規模（按類型和複合年成長率）（2025-2032）

• 市場概覽
• 大腸直腸癌
• 胰臟癌
• 卵巢癌
• 乳癌
• 甲狀腺癌
• 其他

癌胚抗原市場規模（按性別和複合年成長率） (2025-2032)

• 市場概覽
• 男性
• 女士

癌胚抗原市場規模（依產品和複合年成長率） (2025-2032)

• 市場概覽
• CD66a
• CD66b
• CD66c
• CD66d
• CD66e
• CD66f

癌胚抗原市場規模（按測試和複合年成長率） (2025-2032)

• 市場概覽
• 分子檢測
• 血清檢測

癌胚抗原市場規模（依最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 醫院和診所
• 研究組織
• 手術中心
• 其他

癌胚抗原市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• F. Hoffmann-La Roche Ltd.（Switzerland）
• Thermo Fisher Scientific Inc.（USA）
• Quest Diagnostics Incorporated（USA）
• Abbott Laboratories（USA）
• Merck KGaA（Germany）
• Laboratory Corporation of America Holdings（USA）
• Siemens Healthineers AG（Germany）
• Bio-Rad Laboratories, Inc.（USA）
• Creative Diagnostics（USA）
• Aviva Systems Biology Corporation（USA）
• Omega Diagnostics Ltd.（UK）
• RayBiotech, Inc.（USA）
• Boster Biological Technology（USA）
• Diazyme Laboratories Inc.（USA）
• GenScript Corporation（USA）
• Lee BioSolutions（USA）
• Danaher Corporation（USA）
• Novartis AG（Switzerland）
• Agilent Technologies, Inc.（USA）

結論和建議

Carcinoembryonic Antigen Market size was valued at USD 2.6 billion in 2023 and is poised to grow from USD 2.72 billion in 2024 to USD 3.96 billion by 2032, growing at a CAGR of 4.8% during the forecast period (2025-2032).

The global Carcinoembryonic Antigen (CEA) market is experiencing robust growth, primarily driven by the rising incidence of cancers, particularly colorectal cancer, which is a key application of CEA testing. There is an increasing focus on early cancer detection and monitoring, leading to heightened demand for tumor markers like CEA. The worldwide surge in cancer prevalence, especially colorectal cancer, has intensified the need for efficient diagnostic solutions, with CEA being a trusted tumor marker for routine cancer screenings. Advancements in diagnostic technologies such as immunoassays and biomarker discovery are enhancing the accuracy and efficiency of CEA testing. However, cost constraints, especially in regions with limited healthcare budgets, remain a significant barrier to market expansion, particularly in developing countries.

Top-down and bottom-up approaches were used to estimate and validate the size of the Carcinoembryonic Antigen market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Carcinoembryonic Antigen Market Segments Analysis

Global Carcinoembryonic Antigen Market is segmented by Type, Gender, Product, Test, End User and region. Based on Type, the market is segmented into Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Breast Cancer, Thyroid Cancer and Others. Based on Gender, the market is segmented into Male and Female. Based on Product, the market is segmented into CD66a, CD66b, CD66c, CD66d, CD66e and CD66f. Based on Test, the market is segmented into Molecular Test and Serology Test. Based on End User, the market is segmented into Hospitals & Clinics, Research Institutes, Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Carcinoembryonic Antigen Market

The rising prevalence of various cancers, particularly colorectal cancer, has significantly increased the demand for reliable tumor markers such as Carcinoembryonic Antigen (CEA). The ability of CEA testing to aid in the early detection and monitoring of cancers is a key factor driving its widespread adoption. As healthcare professionals seek effective ways to identify and track cancer progression, the necessity for accurate biomarkers becomes ever more critical, thus further propelling the growth of the CEA market. This trend underscores the importance of early intervention in improving treatment outcomes and patient survival rates.

Restraints in the Carcinoembryonic Antigen Market

A significant constraint in the Carcinoembryonic Antigen (CEA) market is the cost associated with CEA testing. Affordability is a key concern, especially in regions with limited healthcare funding, which restricts wide accessibility and adoption of this testing method. Additionally, the market faces competition from alternative diagnostic tools and technologies, including advanced imaging techniques and liquid biopsies, which could further divert attention and resources away from a heavy reliance on CEA testing. These factors collectively pose challenges that may impede the growth and widespread implementation of CEA testing in clinical settings.

Market Trends of the Carcinoembryonic Antigen Market

The Carcinoembryonic Antigen (CEA) market is experiencing a notable trend driven by the rising integration of advanced technologies in testing methodologies. Innovations such as novel immunoassays and enhanced biomarker discovery are significantly improving the accuracy and effectiveness of CEA diagnostics. This technological evolution not only enhances cancer detection capabilities but also broadens the application of CEA beyond traditional oncology, encompassing areas such as personalized medicine and preventive healthcare. As healthcare systems increasingly adopt these sophisticated diagnostic tools, the demand for CEA-related products is poised for substantial growth, positioning the market for sustained expansion in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Carcinoembryonic Antigen Market Size by Type & CAGR (2025-2032)

• Market Overview
• Colorectal Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Breast Cancer
• Thyroid Cancer
• Others

Global Carcinoembryonic Antigen Market Size by Gender & CAGR (2025-2032)

• Market Overview
• Male
• Female

Global Carcinoembryonic Antigen Market Size by Product & CAGR (2025-2032)

• Market Overview
• CD66a
• CD66b
• CD66c
• CD66d
• CD66e
• CD66f

Global Carcinoembryonic Antigen Market Size by Test & CAGR (2025-2032)

• Market Overview
• Molecular Test
• Serology Test

Global Carcinoembryonic Antigen Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Research Institutes
• Surgical Centers
• Others

Global Carcinoembryonic Antigen Market Size & CAGR (2025-2032)

• North America (Type, Gender, Product, Test, End User)
  • US
  • Canada
• Europe (Type, Gender, Product, Test, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Gender, Product, Test, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Gender, Product, Test, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Gender, Product, Test, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratory Corporation of America Holdings (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aviva Systems Biology Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omega Diagnostics Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RayBiotech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boster Biological Technology (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diazyme Laboratories Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lee BioSolutions (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations